A 2008 clinical trial studying recent-onset patients with T1D showed that GAD65-alum treatment preserved residual c-peptide [14], but two ensuing trials showed no effect of GAD65-alum on c-peptide [15,16]. This evidence concerns the gene GAD2 and type 1 diabetes mellitus.